The PI3K/AKT/mTOR (PAM) signaling pathway is crucial in regulating cell survival, growth, and the cell cycle. Its complex connections with other pathways can lead to cancer when disrupted. This review in Molecular Cancer, led by N2CR member Dr Alan Prem Kumar, with a team of experts in the PI3K and cancer space, explores PAM pathway dysregulations in cancer and investigates the effectiveness of PI3K, AKT, and mTOR inhibitors alone and in combination with other therapies to combat treatment resistance. Additionally, it delves into the role of PAM signaling in immunology and immunotherapies.

Read more here: https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01827-6